Food and Drug Administration

Antiviral Drugs Advisory Committee

May 14, 2003




The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Valacyclovir Supplemental NDA 20-550, Dr. Birnkrant, FDA (HTM) (PPT)

Genital Herpes: Epidemiology and Public Health Perspectives, Dr. H. Handsfield, MD U. of Washington (HTM) (PPT)

Suppressive Therapy With Valtrex® (valacyclovir HCI) Caplets to Reduce the Frequency of Transmission of Genital Herpes, GlaxoSmithKline (PDF)

Valtrex® (valacyclovir HCI) Caplets, Dr. Harry Haverkos, MD and Dr. Fraser Smith, PhD, FDA (HTM) (PPT)